These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

556 related articles for article (PubMed ID: 31729779)

  • 1. The vicious cycle between α-synuclein aggregation and autophagic-lysosomal dysfunction.
    Bellomo G; Paciotti S; Gatticchi L; Parnetti L
    Mov Disord; 2020 Jan; 35(1):34-44. PubMed ID: 31729779
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation of β-Glucocerebrosidase Reduces Pathological α-Synuclein and Restores Lysosomal Function in Parkinson's Patient Midbrain Neurons.
    Mazzulli JR; Zunke F; Tsunemi T; Toker NJ; Jeon S; Burbulla LF; Patnaik S; Sidransky E; Marugan JJ; Sue CM; Krainc D
    J Neurosci; 2016 Jul; 36(29):7693-706. PubMed ID: 27445146
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autophagy and Alpha-Synuclein: Relevance to Parkinson's Disease and Related Synucleopathies.
    Xilouri M; Brekk OR; Stefanis L
    Mov Disord; 2016 Feb; 31(2):178-92. PubMed ID: 26813776
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Saposin C, Key Regulator in the Alpha-Synuclein Degradation Mediated by Lysosome.
    Ruz C; Barrero FJ; Pelegrina J; Bandrés-Ciga S; Vives F; Duran R
    Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233303
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autophagic lysosome reformation dysfunction in glucocerebrosidase deficient cells: relevance to Parkinson disease.
    Magalhaes J; Gegg ME; Migdalska-Richards A; Doherty MK; Whitfield PD; Schapira AH
    Hum Mol Genet; 2016 Aug; 25(16):3432-3445. PubMed ID: 27378698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant pro-CTSD (cathepsin D) enhances SNCA/α-Synuclein degradation in α-Synucleinopathy models.
    Prieto Huarcaya S; Drobny A; Marques ARA; Di Spiezio A; Dobert JP; Balta D; Werner C; Rizo T; Gallwitz L; Bub S; Stojkovska I; Belur NR; Fogh J; Mazzulli JR; Xiang W; Fulzele A; Dejung M; Sauer M; Winner B; Rose-John S; Arnold P; Saftig P; Zunke F
    Autophagy; 2022 May; 18(5):1127-1151. PubMed ID: 35287553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel glucosylceramide synthase inhibitor attenuates alpha synuclein pathology and lysosomal dysfunction in preclinical models of synucleinopathy.
    Cosden M; Jinn S; Yao L; Gretzula CA; Kandebo M; Toolan D; Hatcher NG; Ma L; Lemaire W; Adam GC; Burlein C; Minnick C; Flick R; Watt ML; Mulhearn J; Fraley M; Drolet RE; Marcus JN; Smith SM
    Neurobiol Dis; 2021 Nov; 159():105507. PubMed ID: 34509608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Age-dependent accumulation of oligomeric SNCA/α-synuclein from impaired degradation in mutant LRRK2 knockin mouse model of Parkinson disease: role for therapeutic activation of chaperone-mediated autophagy (CMA).
    Ho PW; Leung CT; Liu H; Pang SY; Lam CS; Xian J; Li L; Kung MH; Ramsden DB; Ho SL
    Autophagy; 2020 Feb; 16(2):347-370. PubMed ID: 30983487
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autophagy lysosomal pathway dysfunction in Parkinson's disease; evidence from human genetics.
    Senkevich K; Gan-Or Z
    Parkinsonism Relat Disord; 2020 Apr; 73():60-71. PubMed ID: 31761667
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lysosomal functions and dysfunctions: Molecular and cellular mechanisms underlying Gaucher disease and its association with Parkinson disease.
    Horowitz M; Braunstein H; Zimran A; Revel-Vilk S; Goker-Alpan O
    Adv Drug Deliv Rev; 2022 Aug; 187():114402. PubMed ID: 35764179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Cleaning Crew: The Pursuit of Autophagy in Parkinson's Disease.
    Parekh P; Sharma N; Gadepalli A; Shahane A; Sharma M; Khairnar A
    ACS Chem Neurosci; 2019 Sep; 10(9):3914-3926. PubMed ID: 31385687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular mechanisms of α-synuclein and GBA1 in Parkinson's disease.
    Stojkovska I; Krainc D; Mazzulli JR
    Cell Tissue Res; 2018 Jul; 373(1):51-60. PubMed ID: 29064079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Parkinson's disease: acid-glucocerebrosidase activity and alpha-synuclein clearance.
    Blanz J; Saftig P
    J Neurochem; 2016 Oct; 139 Suppl 1():198-215. PubMed ID: 26860955
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cysteine cathepsins are essential in lysosomal degradation of α-synuclein.
    McGlinchey RP; Lee JC
    Proc Natl Acad Sci U S A; 2015 Jul; 112(30):9322-7. PubMed ID: 26170293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduced glucocerebrosidase is associated with increased α-synuclein in sporadic Parkinson's disease.
    Murphy KE; Gysbers AM; Abbott SK; Tayebi N; Kim WS; Sidransky E; Cooper A; Garner B; Halliday GM
    Brain; 2014 Mar; 137(Pt 3):834-48. PubMed ID: 24477431
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The lysosomal β-glucocerebrosidase strikes mitochondria: implications for Parkinson's therapeutics.
    Rubilar JC; Outeiro TF; Klein AD
    Brain; 2024 Aug; 147(8):2610-2620. PubMed ID: 38437875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Constitutive silencing of LRRK2 kinase activity leads to early glucocerebrosidase deregulation and late impairment of autophagy in vivo.
    Albanese F; Mercatelli D; Finetti L; Lamonaca G; Pizzi S; Shimshek DR; Bernacchia G; Morari M
    Neurobiol Dis; 2021 Nov; 159():105487. PubMed ID: 34419621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The GBA1 K198E Variant Is Associated with Suppression of Glucocerebrosidase Activity, Autophagy Impairment, Oxidative Stress, Mitochondrial Damage, and Apoptosis in Skin Fibroblasts.
    Perez-Abshana LP; Mendivil-Perez M; Jimenez-Del-Rio M; Velez-Pardo C
    Int J Mol Sci; 2024 Aug; 25(17):. PubMed ID: 39273169
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autophagic- and Lysosomal-Related Biomarkers for Parkinson's Disease: Lights and Shadows.
    Xicoy H; Peñuelas N; Vila M; Laguna A
    Cells; 2019 Oct; 8(11):. PubMed ID: 31731485
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting the GBA1 pathway to slow Parkinson disease: Insights into clinical aspects, pathogenic mechanisms and new therapeutic avenues.
    Menozzi E; Toffoli M; Schapira AHV
    Pharmacol Ther; 2023 Jun; 246():108419. PubMed ID: 37080432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.